Potassium chloride

Generic Name: Potassium chloride

Brand Names: Bi-peglyte, Bss, Bss Ophthalmic Solution, Cardioplegic, Citrasate, Colyte, Dextrose and Electrolyte No. 75, Diphen, Eye Stream, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Glycerolyte 57, Golytely, H.E.L.P.bicel, Hemosate Ultra, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S pH 7.4, Isoplate, K 45, K-tab, Klor-con, Lactated Ringers, Moviprep, Naturalyte, Normosol-R, Nulytely, Nxstage Pureflow, Olimel, Peglyte, Periolimel, Phoxillum, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasma-lyte R, Plasmalyte A, Plegisol, Plenvu, Pokonza, Prismasol, Procalamine 3, Ringers, Selectbag One, Suflave, Tis-U-sol

Drug Type: Small Molecule

Chemical Formula: ClK

CAS Number: 7447-40-7

Unique Ingredient Identifier: 660YQ98I10

Background: A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion.

Indication: For use as an electrolyte replenisher and in the treatment of hypokalemia.

Associated Conditions: Dehydration, Dry Mouth, Hypokalemia, Hypotonic Dehydration, Hypovolaemia, Isotonic Dehydration, Markedly Reduced Food Intake, Metabolic Acidosis, Hypodermoclysis, Mild Metabolic acidosis, Mild, moderate Metabolic Acidosis, Ocular edema

Associated Therapies: Acid- Base Balance, Bowel preparation therapy, Electrolyte replacement, Fluid replacement therapy, Haemofiltration, Hemodialysis Treatment, Parenteral Nutrition, Parenteral rehydration therapy, Plasma Volume Replacement, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy

Clinical Trials

Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients During Orthopaedic Surgery

Not Applicable

Completed

Conditions: Total Fluid Volume Increased

Interventions: Drug: Lactate Ringers
Drug: Hydroxyethyl Starch

First Posted Date: 2015-02-12

Last Posted Date: 2016-03-24

Lead Sponsor: Yuanyuan Zhang

Target Recruit Count: 120

Registration Number: NCT02361736

Locations: 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China

Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF

Phase 2

Completed

Conditions: Heart Failure
Diastolic Heart Failure

Interventions: Drug: KNO3
Drug: KCl

First Posted Date: 2014-10-03

Last Posted Date: 2017-10-03

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 12

Registration Number: NCT02256345

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: NER1006
Drug: Moviprep

First Posted Date: 2013-04-18

Last Posted Date: 2013-04-18

Lead Sponsor: Norgine

Target Recruit Count: 161

Registration Number: NCT01834742

Locations: 🇷🇴
Pierrel Research HP-RO-SRL, Timisoara, Romania

Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter

Phase 4

Completed

Conditions: Atrial Fibrillation
Atrial Flutter

Interventions: Drug: Potassium chloride
Drug: Glucose 50 MG/ML

First Posted Date: 2013-03-26

Last Posted Date: 2018-07-31

Lead Sponsor: Diakonhjemmet Hospital

Target Recruit Count: 143

Registration Number: NCT01818583

Locations: 🇳🇴
Diakonhjemmet Hospital, Oslo, Norway

Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management

Phase 2

Completed

Conditions: Pain

Interventions: Drug: Triamcinolone hexacetonide
Drug: Lactated Ringers

First Posted Date: 2013-01-18

Last Posted Date: 2020-10-08

Lead Sponsor: University of Florida

Target Recruit Count: 24

Registration Number: NCT01770912

Locations: 🇺🇸
University of Florida College of Dentistry, Gainesville, Florida, United States

Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation

Phase 3

Completed

Conditions: Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.

Interventions: Drug: MOVIPREP

First Posted Date: 2012-11-26

Last Posted Date: 2014-05-15

Lead Sponsor: Takeda

Target Recruit Count: 140

Registration Number: NCT01732692

A Comparison of 5 Low Volume Bowel Preparations

Phase 4

Completed

Conditions: Bowel Preparation for Colonoscopy

Interventions: Drug: SUPREP
Drug: MiraLAX
Drug: MoviPrep
Other: Gatorade

First Posted Date: 2012-11-01

Last Posted Date: 2017-03-24

Lead Sponsor: Gastroenterology Services, Ltd.

Target Recruit Count: 1079

Registration Number: NCT01719653

Locations: 🇺🇸
Gastroenterology Services, Downers Grove, Illinois, United States

Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy

Phase 2

Completed

Conditions: Colon Cancer

Interventions: Drug: NER1006
Drug: MOVIPREP

First Posted Date: 2012-10-26

Last Posted Date: 2014-11-20

Lead Sponsor: Norgine

Target Recruit Count: 240

Registration Number: NCT01714466

Locations: 🇩🇪
PAREXEL International Early Product Development Unit, Berlin, Germany
🇩🇪
Parexel International GmbH, Berlin, Germany

A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)

Phase 4

Completed

Conditions: Colorectal Cancer

Interventions: Drug: MOVIPREP
Drug: CitraFleet

First Posted Date: 2012-09-21

Last Posted Date: 2015-03-31

Lead Sponsor: Norgine

Target Recruit Count: 398

Registration Number: NCT01689792

Locations: 🇩🇪
Klinikum Aschaffenburg, Aschaffenburg, Germany

Study of Efficacy and Tolerability of Various Bowel Preps in Diabetic Patients

Not Applicable

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Golytely (polyethylene glycol electrolyte lavage solution) and placebo
Drug: split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo
Drug: split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl

First Posted Date: 2012-02-15

Last Posted Date: 2018-09-07

Lead Sponsor: University of Oklahoma

Target Recruit Count: 212

Registration Number: NCT01533688

Locations: 🇺🇸
Oklahoma VA Medical Center, Oklahoma City, Oklahoma, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy